Cost-effectiveness of Camrelizumab Plus Carboplatin and Pemetrexed in the First-line Treatment of Patients with Advanced Non-squamous Non-small-cell Lung Cancer

OBJECTIVE To evaluate the cost-effectiveness of camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in the first-line treatment of patients with advanced non-squamous non-small-cell lung cancer from the perspective of the health care system in the context of new national basic medical care insurance medicine catalogue in 2020. METHODS Based on a clinical trial conducted in Chinese patients(CameL), the partitioned survival model was established to analyze the incremental cost-effectiveness in experimental group(camrelizumab plus carboplatin and pemetrexed), compared with control group chemotherapy alone. Deterministic sensitivity analysis and probabilistic sensitivity analysis were performed. RESULTS The basic analysis showed that the incremental cost-effectiveness ratio of experimental group versus control group was 164 271.19 yuan/quality-adjusted life year(QALY), which was lower than the willingness to pay threshold of three times per capita GDP of China(217 341 yuan). Deterministic sensitivity analysis implied that the chemotherapy drugs used in the experimental group was one of the main influencing factors of the incremental cost-effectiveness ratio. Probabilistic sensitivity analysis showed that the cost-effectiveness probability for the experimental group was 82.0%. CONCLUSION For patients with advanced non-squamous non-small-cell lung cancer, camrelizumab as first-line treatment is cost-effectiveness.